SUPPLEMENTAL INFORMATION

Table S1. COVID-19 vaccination by study group compared to North Carolina and US by quartile of interview or follow-up call dates

Characteristic	ILON Metro (n=90) (n=97) (n=92)		Metro (n=92)	JHU-REACH study population (n=279)	North Carolina ^a	USª
Completed initial COVID-19		((p op and a control of		
·						
vaccination protocol, n (%)						
By December 29, 2021 (Q1)	6/19 (31.6)	18/35 (51.4)	8/16 (50)	32/70 (45.7)	(56.7)	(61.9)
By January 10, 2022 (Q2)	12/33 (36.4)	40/70 (57.1)	19/37 (51.3)	71/140 (50.7)	(57.3)	(62.6)
By March 3, 2022 (Q3)	32/60 (53.3)	44/96 (45.8)	28/54 (51.9)	105/210 (50)	(59.4)	(65)
By July 18, 2022 (Q4)	47 (51.6)	47 (48.5)	51 (55.4)	145 (52)	(62.9)	(67.2)
Received at least one booster						
dose, n (%)						
By December 29, 2021 (Q1)	1/19 (5.3)	1/35 (2.9)	0 (0)	2/70 (2.9)	(11.3)	(20.5)
By January 10, 2022 (Q2)	3/33 (9.1)	9/70 (12.9)	5/37 (13.5)	17/140 (12.1)	(12.5)	(22.8)
By March 3, 2022 (Q3)	6/60 (10)	10/96 (10.4)	10/54 (18.5)	26/210 (12.4)	(15)	(28.5)
By July 18, 2022 (Q4)	12 (13.2)	10 (10.3)	19 (20.7)	41 (14.7)	(17.7)	(32.3)
Answered follow-up call, n (%)	73 (81.1)	88 (90.7)	82 (89.1)	243 (87.1)	-	-

Follow-up or interview (if did not	2/10/2022	1/3/2022	1/11/2022	1/10/2022		
answer follow-up) call dates,	(12/29/2021-	(11/3/2021-	(1/03/2022-	(12/29/2021-	-	-
median (IQR)	3/29/2022)	1/11/2022)	4/11/2022)	3/2/2022)		

^aUS CDC estimates from Our World in Data visualization (1)

Note: ILO refers to study participants living in a household with at least one adult working at an industrial hog or poultry operation, meatpacking plant, or animal rendering plant; ILON refers to participants living nearby these facilities without any known occupational exposure to livestock; Metro refers to participants living in metropolitan areas of North Carolina. Participants who reported vaccination but did not provide a corresponding date are included as by July 18, 2022, final date of interviews and follow-up calls.

Table S2. Self-reported infection prevention behaviors and health history by study group, North Carolina, USA, 2021-2022

Characteristic, n (%)	ILO n=90		ILC	N n=97	Metro n=92		p -
	(80 ho	useholds)	(80 hc	ouseholds)	(80 ho	ouseholds)	valueª
Infection prevention							
behaviors							
Reduced physical contact							0.16
with people outside your							
home							
Yes, all household	65	(71.4)	81	(83.5)	69	(75)	
members							
Yes, some but not all	10	(11)	4	(4.1)	6	(6.5)	
household members							
No	9	(9.9)	4	(4.1)	7	(7.6)	
No response	7	(7.7)	8	(8.2)	10	(10.9)	
Avoiding or cancelling							0.05
travel or vacation plans							
Yes	72	(79.1)	75	(77.3)	56	(60.9)	
No	19	(20.9)	21	(21.6)	33	(35.9)	
No response	0		1	(1)	3	(3.3)	
Wearing a mask when out							0.16
in public							
Yes	86	(94.5)	93	(95.9)	83	(90.2)	
No	5	(5.5)	3	(3.1)	9	(9.8)	
			I		I		

Washing hands/using 0 hand sanitizer more 6 frequently 90 (92.8) 86 (93.5)	.62
frequently	
Yes 88 (96.7) 90 (92.8) 86 (93.5)	
No 3 (3.3) 5 (5.2) 5 (5.4)	
No response 0 (0) 2 (2.1) 1 (1.1)	
At times (last 2 w) you	
interacted with people	
inside	
How often did you 0	.41
maintain a 6 ft distance	
from others?	
Always 67 (73.6) 78 (80.4) 68 (73.9)	
Sometimes 24 (26.4) 17 (17.5) 21 (22.8)	
Never 0 (0) 1 (1) 2 (2.2)	
No response 0 (0) 1 (1) 1 (1.1)	
How often did you wear a 0	.06
mask?	
Always 74 (81.3) 82 (84.5) 66 (71.7)	
Sometimes 17 (18.7) 13 (13.4) 22 (23.9)	
Never 0 (0) 1 (1) 4 (4.3)	
No response 0 (0) 1 (1) 0 (0)	

Health history							
Do you have any of the							
following chronic							
conditions?							
Hypertension	25	(27.5)	28	(28.9)	22	(23.9)	0.77
Diabetes	15	(16.5)	17	(17.5)	10	(10.9)	0.43
Asthma	9	(9.9)	5	(5.2)	13	(14.1)	0.10
Depression	2	(2.2)	6	(6.2)	12	(13)	0.03
Cardiovascular disease	2	(2.2)	6	(6.2)	5	(5.4)	0.38
Cancer	4	(4.4)	3	(3.1)	1	(1.1)	0.41
diagnosis/treatment							
(past 12 mo)							
Chronic kidney disease	1	(1.1)	4	(4.1)	3	3.3	0.44
Autoimmune disease	1	(1.1)	2	(2.1)	2	2.2	0.83
Chronic obstructive	2	(2.2)	1	(1)	1	(1.1)	0.76
pulmonary disease							
(COPD)							
Immunocompromised	2	(2.2)	0	(0)	1	(1.1)	0.35
condition							
Other chronic lung	2	(2.2)	1	(1)	0	(0)	0.36
disease							
Sickle cell anemia	1	(1.1)	0	(0)	1	(1.1)	0.59
Do you have seasonal	42	(46.2)	49	(50.5)	57	(62)	0.04
allergies?							
					I		

Have you gotten or plan	36	(39.6)	48	(49.5)	44	(47.8)	0.30
to get a flu shot this year?							
Fever with a cough at the	19	(20.9)	15	(15.5)	17	(18.5)	0.33
same time or fever with a							
sore throat at the same							
time (past yr)? ^b							
Since February 1, 2020,	22	(24.2)	18	(18.6)	18	(19.6)	0.28
have you thought you had							
COVID-19?							

^ap-value associated with Chi-square test statistic

Note: ILO refers to study participants living in a household with at least one adult working at an industrial hog or poultry operation, meatpacking plant, or animal rendering plant; ILON refers to participants living nearby these facilities without any known occupational exposure to livestock; Metro refers to participants living in metropolitan areas of North Carolina.

^bCDC definition of influenza-like illness (2)

	Group	Date quartile	Black, Hispanic, Other	HS+ or not	>1 person per bedroom or not	Physical distancing	Masking or not	Vaccinated
Group	1	0.39	0.17	0.25	0.23	0.11	0.12	0.11
Date quartile	NA	1	0.18	0.14	0.18	0.23	0.14	0.42
Black, Hispanic, Other	NA	NA	1	0.21	0.12	0.10	0.10	0.11
HS+ or not	NA	NA	NA	1	0.09	0.01	0.03	0.13
>1 person per bedroom or not	NA	NA	NA	NA	1	0.06	0.09	0.02
Physical distancing	NA	NA	NA	NA	NA	1	0.05	0.04
Masking or not	NA	NA	NA	NA	NA	NA	1	0.03
Vaccinated	NA	NA	NA	NA	NA	NA	NA	1

Figure S1. Correlation matrix (Cramer's V) between factors associated with SARS-CoV-2 infection-induced IgG prevalence, categorized as in Table 3.




Figure S2. SARS-CoV-2 infection-induced IgG prevalence over time by cohort; REACH ILO, ILON, and Metro groups split into participants sampled before vs. after the median sampling date, September 6, 2021, for better comparability with other cohorts over time. Note: REACH refers to our study population and collaboration with the Rural Empowerment Association for Community Help (REACH); ILO refers to study participants living in a household with at least one adult working at an industrial hog or poultry operation, meatpacking plant, or animal rendering plant; ILON refers to participants living nearby these facilities without any known occupational exposure to livestock; Metro refers to participants living in metropolitan areas of North Carolina.

Table S3. Selected participant characteristics by study group compared to Atlanta health care worker (HCW) cohort and Cabarrus County, NC general population cohort

Characteristic, n (%)	ILO (n=90)	ILON (n=97)	Metro	JHU-REACH	Atlanta HCW (n=301)	Cabarrus
			(n=92)	study		County
				population		(n=300)
				(n=279)		
SARS-CoV-2 infection-	46/73 (63%)	36/84 (43%)	37/76 (49%)	119/233	71/306 (23.2%)	23/270
induced IgG ^a				(51.1%)		(8.5%)
Sampling date, median	2/9/2022	6/6/2021	8/18/2021	9/6/2021	_	_
(range)	(4/2/2021-	(3/8/2021-	(2/23/2021-	(2/23/2021-		
	7/18/2022)	6/3/2022)	6/7/2022)	7/18/2021)		
					Latest follow-up 6	Latest
					months post-enrollment	follow-up
					(1/2021-12/2021)	11/2021
Age in years, median (range)	41.5 (13-67)	50 (5-83)	37 (9-74)	41 (5-83)	_	_
					172 (57.1) <40 years	Median 56
						(IQR 47,
						67)

Ge	nder						
	Female	47 (52)	54 (56)	67 (73)	139 (59.7)	231 (76.7)	183 (61.0)
	Male	43 (48)	42 (43)	25 (27)	94 (40.3)	70 (23.3)	117 (39.0)
	No response						
Ra	ce/ethnicity						
	Black/African American	79 (88)	83 (86)	74 (80)	236 (84.5)	33 (11.0)	51 (17.0)
	Hispanic/Latino	8 (9)	11 (11.3)	3 (3.3)	22 (7.9)	13 (4.3)	33 (11.0)
	White/Caucasian	1 (1.1)	1 (1)	8 (8.7)	10 (3.6)	219 (72.8)	230 (76.7)
	Both Black and White	0 (0)	1 (1)	2 (2.2)	3 (1.1)	_	_
	Asian-American	0 (0)	0 (0)	1 (1)	1 (0.004)	29 (9.6)	0 (0)
	Other or no response	2 (2.2)	1 (1)	3 (3.3)	6 (2.2)	20 (6.6)	_
Ed	ucation						
	High school	65 (71)	53 (55)	37 (40)	155 (55.6)	_	19 (6.3)
	diploma/GED or less						
	Post-high school	26 (29)	42 (43)	53 (58)	121 (43.3)	_	180 (93.3)
	No response	0 (0)	2 (2.2)	2 (2.2)	4 (1.4)	_	1 (0.3)
		I	I	I	I		I

Household members, mean (SD)	2.7 (1.4)	2.1 (1.3)	2.2 (1.2)	2.3 (1.3)	_	Median 2 (IQR 2, 4)
Health insurance ^b						
Company health	30 (33)	33 (34)	56 (61)	119 (42.7)	_	169 (56.3)
insurance plan						
Public health insurance	34 (38)	35 (36)	17 (19)	86 (30.8)	_	94 (31.3)
Private health insurance	15 (17)	16 (17)	10 (11)	41 (14.7)	_	12 (4.2)
No health insurance	12 (13)	15 (16)	8 (9)	35 (12.5)	_	14 (4.7)
Other or no response	2 (2)	0 (0)	1 (1.1)	3 (1.1)	_	25 (8.3)

^aNumber of samples tested for SARS-CoV-2-specific N IgG does not necessarily match size of study population group. Not all JHU-REACH samples were tested; Atlanta HCW and Cabarrus County N IgG results are only shown for the latest follow-up visit; some Atlanta HCW participants from the latest follow-up visit were not included for analysis in the manuscript from which participant characteristics were extracted (3)

^bParticipants could select more than one option.

Note: ILO refers to study participants living in a household with at least one adult working at an industrial hog or poultry operation, meatpacking plant, or animal rendering plant; ILON refers to participants living nearby these facilities without any known occupational exposure to livestock; Metro refers to participants living in metropolitan areas of North Carolina; "—" refers to data not available.

REFERENCES

- State-by-state data on COVID-19 vaccinations in the United States. Our World in Data. https://ourworldindata.org/us-states-vaccinations. Retrieved 23 August 2022.
- 2. CDC. 2022. Weekly U.S. Influenza Surveillance Report. Centers for Disease Control and Prevention. https://www.cdc.gov/flu/weekly/index.htm. Retrieved 12 August 2022.
- 3. Howard-Anderson JR, Adams C, Dube WC, Smith TC, Sherman AC, Edupuganti N, Mendez M, Chea N, Magill SS, Espinoza DO, Zhu Y, Phadke VK, Edupuganti S, Steinberg JP, Lopman BA, Jacob JT, Fridkin SK, Collins MH. 2022. Occupational risk factors for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection among healthcare personnel: A 6-month prospective analysis of the COVID-19 Prevention in Emory Healthcare Personnel (COPE) Study. Infect Control Hosp Epidemiol 1–8.